Share repurchase update gives investors fresh data point

Novo Nordisk (NVO) has updated investors on its ongoing share repurchase programme, with plans to buy back B shares for up to DKK 11.2 billion through 1 February 2027.

At a share price of $49.07, Novo Nordisk has seen a 30 day share price return of 11.83% and a 90 day share price return of 20.24%, yet its 1 year total shareholder return is down 24.60%. This suggests that recent momentum contrasts with weaker longer term outcomes as investors weigh progress in GLP 1 pills and ongoing capital returns against past performance.

If Novo Nordisk’s recent moves have your attention, it could be a good moment to see what else is changing healthcare with AI by reviewing the 40 healthcare AI stocks.

After a sharp rebound in Novo Nordisk’s share price and an active buyback programme in the background, the key issue now is simple: does the current valuation still leave enough upside to compensate for the risks?

Most Popular Narrative: 52.3% Undervalued

According to the most followed valuation narrative, Novo Nordisk’s fair value of $102.97 sits well above the last close at $49.07, which frames today’s share repurchases against a much higher long term target.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative assigns such a high fair value to Novo Nordisk? It leans heavily on GLP 1 market expansion, richer margins, and a future earnings multiple that sits closer to sector leaders than the current share price suggests.

Result: Fair Value of $102.97 (UNDERVALUED)

However, this Novo Nordisk narrative still faces real pressure if GLP 1 adoption or pricing disappoints, or if key regulatory approvals are delayed or rejected.

Next Steps

With Novo Nordisk drawing mixed sentiment from both risks and rewards, now is a useful time to review the underlying data yourself and decide whether the current narrative really fits your view by weighing its 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

Once you have formed a view on Novo Nordisk, do not stop there. Use focused stock lists to spot other opportunities that fit your portfolio goals.

• Target potential bargains early by scanning companies that screen as high quality yet potentially mispriced using the 44 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that have paid out yields above 5% through the 8 dividend fortresses.
• Lower overall portfolio risk by concentrating on companies with sturdy finances and consistent fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.